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Herpes	simplex	viruses	(HSVs)	are	highly	prevalent	neurotropic	viruses.	While	they	can	replicate	lytically	in	
cells	of	the	epithelial	lineage,	causing	lesions	on	mucocutaneous	surfaces,	HSVs	also	establish	latent	infec-
tions	in	neurons,	which	act	as	reservoirs	of	virus	for	subsequent	reactivation	events.	Immunological	control	of	
HSV	involves	activation	of	innate	immune	pattern-recognition	receptors	such	as	TLR3,	which	detects	double-
stranded	RNA	and	induces	type	I	IFN	expression.	Humans	with	defects	in	the	TLR3/IFN	pathway	have	an	ele-
vated	susceptibility	to	HSV	infections	of	the	CNS.	However,	it	is	not	known	what	cell	type	mediates	the	role	of	
TLR3	in	the	immunological	control	of	HSV,	and	it	is	not	known	whether	TLR3	sensing	occurs	prior	to	or	after	
CNS	entry.	Here,	we	show	that	in	mice	TLR3	provides	early	control	of	HSV-2	infection	immediately	after	entry	
into	the	CNS	by	mediating	type	I	IFN	responses	in	astrocytes.	Tlr3–/–	mice	were	hypersusceptible	to	HSV-2	
infection	in	the	CNS	after	vaginal	inoculation.	HSV-2	exhibited	broader	neurotropism	in	Tlr3–/–	mice	than	it	
did	in	WT	mice,	with	astrocytes	being	most	abundantly	infected.	Tlr3–/–	mice	did	not	exhibit	a	global	defect	in	
innate	immune	responses	to	HSV,	but	astrocytes	were	defective	in	HSV-induced	type	I	IFN	production.	Thus,	
TLR3	acts	in	astrocytes	to	sense	HSV-2	infection	immediately	after	entry	into	the	CNS,	possibly	preventing	
HSV	from	spreading	beyond	the	neurons	mediating	entry	into	the	CNS.
Introduction
Herpes simplex virus 1 (HSV-1) and HSV-2 are human patho-
genic viruses, which can replicate lytically in cells of the epithelial 
lineage and cause mucocutaneous lesions, as seen during orofa-
cial and genital herpes (1). Importantly, HSV-1 and HSV-2 are 
also neurotropic viruses and establish latent infection in neu-
rons, which can thus serve as reservoirs of virus during subse-
quent events of reactivation. Due to their neurotropism, HSVs 
can invade the CNS and cause disease, especially in immunocom-
promised individuals. HSV-1 is a major cause of encephalitis, 
whereas HSV-2 can give rise to meningitis as well as encephalitis, 
sacral radiculitis, and myelitis (1, 2).
Immunological control of HSV involves both the innate and 
adaptive immune system, with important roles ascribed to type I 
IFN, natural killer cells, and CD8+ T cells (3–7). Pattern-recogni-
tion receptor (PRR) activation stimulates expression of inflamma-
tory and antimicrobial genes, such as TNFA and type I IFN, respec-
tively (8). HSV is sensed by a series of PRRs, including TLR3, which 
detects double-stranded RNA (9–13). In addition to TLRs, it has 
been demonstrated that HSV nucleic acids are detected in the cyto-
plasm of infected cells and induce IFN (14–17). The physiological 
importance of cytoplasmic sensing of HSV remains unexplored.
The potential role of TLR3 in viral CNS infections has been 
addressed in several studies. TLR3 is upregulated in the CNS dur-
ing viral infections, including human immunodeficiency virus 
encephalitis and rabies virus infection (18, 19). However, the role 
of TLR3 appears to differ depending on the virus and the infection 
model (20–22), and the emerging picture is that TLR3 can play both 
protective and pathological roles. For instance, there is evidence for 
TLR3 playing critical roles in protection against West Nile virus 
encephalitis, but there is also evidence that this PRR drives break-
down of the blood-brain barrier during infection with the same 
virus and potentiates immunopathology (20, 21). In a series of 
publications, Casanova, Zhang, and associates have identified and 
described patients with defects in the TLR3/IFN axis, all of whom 
had HSV-1 encephalitis, without a history of elevated susceptibility 
to other infections (5, 23–25). These studies indicate that, in case of 
HSV-1 infection in childhood, TLR3-mediated antiviral responses 
are needed for protection of the CNS but are redundant for host 
defense in the periphery. This work was followed by a case report 
on a patient with TLR3 deficiency, who experienced repeated reac-
tivation of HSV-2 and development of Mollaret meningitis (26). 
Thus, clinical data suggest a key role for TLR3 in control of HSV 
infections in the CNS. However, the cells that sense HSV in a TLR3-
dependent manner and activate essential defense actions in vivo 
remain unknown. In addition, it has not been established whether 
the role of TLR3 in defense against HSV infections occurs prior to 
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neuro-entry or within the CNS. In this work, we report that TLR3 
is responsible for early control of HSV-2 after entry into the CNS 
by mediating the IFN-β response in astrocytes, hence limiting viral 
replication in neurons and restricting HSV to this cell type.
Results
Mice deficient in TLR3 or the type I IFN system are hypersusceptible to 
HSV-2 infection in the CNS after vaginal infection. To examine the 
role of TLR3 in prevention of HSV infections in mice, we infected 
Tlr3–/– mice with HSV-2 via the vagina. We observed a striking 
defect in preventing disease development in these mice as com-
pared with that in WT control mice (on a B6;129S background) 
(Figure 1A), and this closely resembled the development of disease 
in HSV-2–infected Ifn-α receptor–deficient (Ifnar–/–) mice, which 
were on C57BL/6 background. In these experiments, WT mice of 
each strain exhibited the same degree of disease. Importantly, we 
Figure 1
Tlr3–/– mice are hypersusceptible to HSV-2 infection. Disease development after intravaginal infection with HSV-2 (6.7 × 104 PFU). (A) Clinical 
score of infected mice from day 1–6 p.i. (B) Percentage of animals with hind limb paralysis on day 6 p.i. (C) Percentage of animals with bladder 
retention on day 6 p.i. (D) Post-mortem urinary retention (white arrow), constipation (blue arrow), and fatty liver (yellow arrow) were observed in 
the infected Tlr3–/– mice. (E) H&E-stained medulla spinalis (original magnification, ×200), cerebellum and cerebrum sections (original magnifica-
tion, ×40) of infected mice day 6 p.i. Second column: staining of medulla spinalis sections with anti-CD45. CD45+ cells are indicated by black 
arrow (original magnification: ×400). The data shown in (A–C) are mean of 3–5 independent experiments on day 6 p.i. (n = 4–12 mice in each 
group per experiment), and (D) are representative pictures of these experiments. *P < 0.05.
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observed that Tlr3–/– and Ifnar–/– mice exhibited particularly strong 
signs of disease in the CNS, with hind limb paralysis and urinary 
retention (Figure 1, A–D, and Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI60893DS1). For comparison, the development of disease in 
Tlr3–/– and Ifnar–/– mice was more pronounced than that in the 
case of Tlr2 and Tlr9 double-deficient mice, which we previously 
reported are susceptible to HSV-2 infection of the CNS after initial 
infection in the vagina (3, 27). In addition, IFN-λ receptor–defi-
cient mice exhibited a phenotype indistinguishable from that of 
WT mice (N. Ank, unpublished observations, and ref. 3).
Microscopy examination of the mice revealed scattered leuko-
cytes in the dorsal lower part of medulla spinalis in the Tlr3–/– mice 
but not in the WT mice (Figure 1E). In the same area, HSV-2– 
infected cells were found in the Tlr3–/– mice but not in the WT 
mice (Figure 2E). Very few leukocytes were observed in the menin-
ges along the medulla spinalis of the Tlr3–/– mice. We observed no 
inflammation in the cerebral cortex, white matter, periventricu-
lar area, cerebellum, or the cerebral or cerebellar meninges. These 
findings suggest that Tlr3–/– mice develop myelitis after vaginal 
HSV-2 infection. Thus, TLR3 and IFNAR deficiency render mice 
susceptible to HSV-2–mediated disease in the CNS after initial 
infection in the peripheral tissue.
In order to examine how the lack of TLR3 affected control 
of virus, we examined the viral load in these mice at the site of 
infection in the periphery (vagina), the site of entry into the CNS 
(medulla spinalis), and potential sites of spread within the CNS 
(cerebellum and cerebrum). As seen in Figure 2A, there was no 
difference in the viral load in vaginal washes harvested on day 2 
postinfection (p.i.) from WT and Tlr3–/– mice, suggesting that early 
control of the virus in the vagina was not dependent on TLR3. In 
the medulla spinalis, virus could be detected from day 4 p.i., and, 
again, no difference was observed between WT and Tlr3–/– mice 
(Figure 2B). By contrast, on day 6 p.i. we observed significantly 
higher HSV-2 titer in the medulla spinalis of Tlr3–/– mice as com-
pared with that in WT mice (Figure 2B). The same was seen for 
Ifnar–/– mice. The virus did not spread efficiently to the cerebellum 
and cerebrum, although Tlr3–/– mice did exhibit a significantly 
elevated viral load in the cerebellum as compared with that in the 
WT mice (Figure 2, C and D). Staining of tissue sections of the 
lumbar medulla spinalis for HSV-2 confirmed extensive infection 
on day 6 p.i. in the Tlr3–/– and Ifnar–/– mice as compared with that 
in the WT mice (Figure 2E). Collectively, TLR3- and IFNAR-defi-
cient mice are highly susceptible to HSV-2 infection in the CNS 
after initial infection in the vagina. TLR3 deficiency did not affect 
control of viral load in the vagina and early entry into the CNS. By 
contrast, the virus replicated to significantly higher titers within 
the medulla spinalis and cerebellum of TLR3-deficient mice.
TLR3-deficient mice do not have a global defect in type I IFN responses 
in the periphery and the CNS. TLR3 has been reported to have impact 
on both innate and adaptive immune responses during virus infec-
tions in the periphery and CNS (13, 20, 21, 28, 29). To look into 
the innate response to HSV-2 infection, we isolated medulla spina-
lis from mice infected with HSV-2 for 6 days and examined expres-
sion of IFNs, IFN-stimulated genes, and inflammatory genes. The 
infection led to strong induction of IFN-β expression and little 
or no induction of IFN-α expression in the WT mice (Figure 3, A 
and B). Interestingly, the elevated susceptibility of Tlr3–/– mice to 
Figure 2
Tlr3–/– and Ifnar–/– mice have elevated viral load in the medulla spinalis on day 6 p.i. The mice were infected intravaginally with HSV-2 (6.7 × 104 
PFUs). (A) Vaginal washes were harvested for quantification of viral load on day 2 p.i. (B) Viral load in the medulla spinalis on days 4 and 6. 
(C) Viral load in the cerebellum on day 6 p.i. (D) Viral load in the cerebrum on day 6 p.i. The dashed line indicates the detection limit. (E) Confocal 
images of the dorsal part of lumbar medulla spinalis from uninfected or infected mice (6 day p.i.). Positive anti–HSV-2 antibody staining is shown 
in green and nuclear staining with DAPI is shown in blue. Scale bar: 50 μm. The data are presented as mean of 3 independent experiments 
(n = 4–6 mice in each group per experiment). *P < 0.05.
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HSV-2 infection in the CNS (Figures 1 and 2) was not associated 
with a global decrease in the expression of type I IFN (Figure 3, A 
and B) or IFN-stimulated genes in the CNS, as demonstrated by 
comparable induction of Cxcl10 in WT and Tlr3–/– mice (Figure 
3C). As expected, the Ifnar–/– mice did not induce Cxcl10, hence 
confirming this chemokine as an IFN-stimulated gene in this 
model (Figure 3C). The inflammatory cytokine TNF-α was also 
strongly induced in the CNS p.i. in a manner independent of TLR3 
and IFNAR (Figure 3D). Examination of the same parameters in 
medulla spinalis from HSV-2–infected Tlr2 and Tlr9 double-defi-
cient mice showed that the response was also independent of these 
PPRs (L.S. Reinert, unpublished observations), suggesting a role 
for other innate immune sensors in induction of the bulk of the 
IFN and cytokine response in the CNS during HSV-2 infection. 
Importantly, several PRRs reported to detect HSV infections were 
found to be expressed in the infected medulla spinalis and to be 
induced in a manner independent of TLR3 but dependent on 
IFNAR expression (Supplemental Figure 2), and, moreover, the 
CXCL10 response of microglia cells to HSV-2 infection in vitro 
was independent of TLR3 (Supplemental Figure 3A).
Examination of the role of TLR3 in peripheral response to HSV 
infection in vivo and in vitro revealed that the early IFN-depen-
dent response in the vagina after genital infection was indepen-
dent of TLR3 (Figure 3E). Moreover, in spleen and peritoneal cells, 
we observed no role for TLR3 in activation of the HSV-2–induced 
CXCL10 response (Supplemental Figure 3, B and C), and this was 
also the case for the response to HSV-1 infection (Supplemental 
Figure 4, A and B). To examine a potential role for TLR3 in acti-
vation of adaptive immune responses after HSV-2 infection, we 
looked for splenic T cells at day 6 p.i. Infection led to elevation 
in the number of total and CD8+ T cells, but with no difference 
between that in WT and Tlr3–/– mice (Supplemental Figure 5, 
A–C). Finally, we found no recruitment of CD8+ cells to the lumbar 
medulla spinalis on day 6 p.i. in either WT or Tlr3–/– mice (Sup-
plemental Figure 5, D–F). Thus, the observed defective control 
of HSV-2 infection in the CNS of Tlr3–/– mice and the associated 
development of disease are not due to a global defect in induction 
of the type I IFN response.
HSV-2 replication occurs in neurons and astrocytes in the medulla spinalis 
of TLR3- and IFNAR-deficient mice. The data presented above suggested 
that the impaired antiviral defense in Tlr3–/– mice was due to a defect 
in immune responses in the microenvironment at the site of viral 
replication, rather than being due to an overall defect in mounting 
innate immune responses to HSV infection in the CNS. HSV-1 and 
HSV-2 are neurotropic but also have the capacity to replicate in a 
wide range of other cell types. We therefore examined whether the 
defect in TLR3 mice led to a broadening of the tropism for HSV-2 
in the CNS beyond neurons. Since, TLR3 is reported to be highly 
expressed by astrocytes (30–33), we focused on this cell type.
Immunohistochemical (IHC) analysis of lumbar medulla spina-
lis sections from HSV-2–infected WT mice revealed that only very 
few HSV-2–positive cells could be found, and most of these were 
neurons (NeuN+) (Figure 4A). In the tissue sections from the lum-
bar medulla spinalis of Tlr3–/– and Ifnar–/– mice, we found many 
more HSV-2–positive cells, many of which were neurons. Impor-
tantly, and in contrast to the WT mice, the virus was not restricted 
to neurons in the Tlr3–/– and Ifnar–/– mice, and staining for astro-
cytes showed that this cell type was productively infected with 
HSV-2 in these 2 mouse strains. This was seen using antibodies 
against 2 different astrocyte markers: S100, which localizes to the 
nucleus, and glial fibrillary acidic protein (GFAP), which localizes 
to the cytoplasm and associates with intermediate filaments. At 
the infected areas of lumbar medulla spinalis — the dorsal funiculi 
and dorsal horn, we found 50% ± 8.3% of astrocytes were infected 
in Tlr3–/– mice, while only 2% ± 1.6% (P < 0.05) of astrocytes in WT 
mice were infected at day 6 p.i.
The data presented in Figure 2, B–D, showed that viral spread 
within the CNS from the medulla spinalis to the cerebellum and 
Figure 3
Expression of cytokines in medulla spinalis is unaltered in 
HSV-2–infected Tlr3–/– mice. (A–D) Expression of type I Ifn, 
Cxcl10, and Tnfa mRNA in the medulla spinalis of mice on 
day 6 after intravaginal HSV-2 infection (6.7 × 104 PFUs). 
Data are normalized to uninfected WT mice and are rep-
resentative of 2–4 independent experiments (n = 5–8 mice 
in each group per experiment). NR, normalized ratio. (E) 
CXCL10 protein expression in vaginal wash on day 2 p.i. 
with HSV-2. The data are reproduced 3 times (n = 5–20 
mice in each group per experiment). *P < 0.05.
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Figure 4
HSV-2 predominately infects neurons and astrocytes in the medulla spinalis of Tlr3–/– mice. (A) Detection of HSV-2, astrocytes, and neurons by 
IHC in the medulla spinalis on 6 days p.i. Dorsal funiculi or dorsal horn stained for S100 and GFAP (both markers for astrocytes), NeuN (neu-
rons), DNA (DAPI), and HSV-2. (B and C) Costaining of thoracic and cervical regions of medulla spinalis for S100 and GFAP, NeuN, DNA, and 
HSV-2. Scale bar: 20 μm; magnification of insets, ×6.4. The data are reproduced twice (n = 4 mice in each group per experiment).
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cerebrum was inefficient, with little or no virus being detected 
in the samples from the cerebrum, regardless the genetic back-
ground. Nevertheless, we noted that the virus spread beyond the 
medulla spinalis more efficiently in the Tlr3–/– mice. The amount 
of infected cells per section was 10 ± 3 in the thoracic part of the 
medulla spinalis of Tlr3–/– mice and 1 ± 2 in case of cervical part. 
While the virus spread inefficiently in WT mice, there were only 
1 ± 2 infected cells per section in thoracic part and no cells in 
cervical part of the medulla spinalis. Interestingly, IHC analysis 
of sections from thoracic and cervical medulla spinalis revealed 
that in these regions HSV-2 was mainly detected in astrocytes 
(Figure 4, B and C). Thus, TLR3 deficiency broadens the tropism 
for HSV-2 in the CNS, rendering not only neurons but also astro-
cytes permissive to the infection.
TLR3-deficient astrocytes are defective in HSV-induced IFN-β produc-
tion and exhibit elevated permissiveness to HSV-2 infection in vitro. The 
observed HSV tropism for astrocytes in Tlr3–/– mice led us to inves-
tigate primary astrocytes in vitro. In particular, we were interested 
in examining the potential relation between TLR3 and type I IFN 
in restriction of HSV-2 in astrocytes. We first examined whether 
TLR3 deficiency altered the efficiency of HSV-2 replication in 
astrocytes. As seen in Figure 5A, HSV-2 infection led to productive 
replication in astrocytes in vitro, and, importantly, a significantly 
higher viral yield was harvested from the supernatants of Tlr3–/– 
and Ifnar–/– astrocytes compared with that from WT cells. Treat-
ment of the Tlr3–/– astrocytes with recombinant IFN-β reduced the 
viral titer to a level below what was seen in WT cells (Figure 5A). 
Examination of the ability of the astrocytes to respond to HSV-2 
infection with an IFN response revealed that the infection trig-
gered expression of IFN-β and CXCL10 RNA and protein in a man-
ner dependent on TLR3 (Figure 5, B–E). Similarly, HSV-1–induced 
CXCL10 expression in astrocytes was also dependent on TLR3 
(Supplemental Figure 3C).
Discussion
HSV-1 and HSV-2 belong to the group of alphaherpesviruses, 
which have a very broad tropism and replicate lytically in many 
cell types, most notably cells of the epithelial and fibroblast cell 
lineages. Importantly, alphaherpesviruses are neurotropic and 
establish latent infections in these cells after retrograde transport 
to the ganglia. Due to the neurotropism, alphaherpesviruses can 
also enter into the CNS, in which they can cause serious diseases. 
Our data suggest that the Ifnar–/– and Tlr3–/– mice developed myeli-
tis after vaginal HSV-2 infection, and exhibited urinary retention, 
constipation, and fatty liver more commonly than WT mice.
An important task for the host is thus to restrict the access of 
HSV to the CNS and spread within the CNS. It has been reported 
that patients with defects in TLR3 are susceptible to HSV infec-
tions in the CNS (24, 26), thus suggesting a role for TLR3 in 
immunological control of these viruses in the peripheral tissue 
prior to neuroinvasion, in the peripheral nervous system, or in the 
CNS. Our present finding that prevention of viral replication and 
Figure 5
TLR3 is required for HSV-mediated induction of IFN-β signaling and resistance against HSV-2 infection in astrocytes. (A) Astrocytes were 
infected with 0.1 MOI of HSV-2 for 6 hours, and extracellular virus was removed by washing. Thirty hours p.i., supernatants were harvested, and 
viral load was determined. IFN-β (25 U/ml) was given 24 hours prior to infection. (B and C) Expression of CXCL10 and IFN-β mRNA in astrocytes 
after HSV-2 infection (0.1 MOI), poly I:C treatment (25 μg/ml), or infection with Sendai virus (0.001 MOI). NR, normalized ratio. (D) CXCL10 
protein expression in astrocytes 24 hours after stimuli. (E) Confocal images of uninfected or HSV-2–infected astrocytes (6 hours). Brefeldin A 
was added to the culture 1 hour p.i. The cells were stained for VP5 (red; major capsid protein), IFN-β (green), and DNA (blue; DAPI). Scale bar: 
5 μm. Similar results were obtained in 3 independent experiments (n = 3 per group per experiment). *P < 0.05.
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spread within the CNS is impaired in TLR3-deficient mice, which 
display unaltered viral loads in peripheral tissue and at early stages 
after entry into the CNS, suggests that the role of TLR3 in HSV 
infection is within the CNS. We found higher viral load in the cer-
ebellum of Tlr3–/– mice compared with that in the Ifnar–/– mice. 
These data indicate that TLR3 has antiviral functions in the cer-
ebellum independent of type I IFN. One possibility is that HSV, in 
addition to spreading to neighboring glial and neuronal cells in 
the lumbal part of the medulla spinalis, may also spread via long 
neurons that reach the cerebellum and that this is controlled in 
a TLR3-dependent but type I IFN–independent way. Moreover, 
we present in vivo and in vitro data suggesting that Tlr3–/– astro-
cytes are more permissive to HSV infection and that this is due to 
impaired type I IFN production by this cell type in the absence of 
TLR3. Thus, we propose that astrocytes sense HSV entry into the 
CNS and mount a type I IFN response, which rapidly restricts the 
virus after neuronal transport into the CNS.
TLR3 is highly expressed in the CNS (Supplemental Figure 6), 
and several studies have examined the expression of PRRs in differ-
ent cell types in the CNS. While microglia cells express most, if not 
all, TLRs, other glial cells and neurons are much more restricted 
in their pattern of TLRs (30, 31). Importantly, TLR3 is selectively 
expressed as the sole nucleic acid–sensing TLR on astrocytes and 
oligodendrocytes (Supplemental Figure 6 and refs. 30, 32, 33), and 
its expression is further elevated by IFN treatment and virus infec-
tions (31). Thus, the pattern of PRR expression in the CNS further 
suggests an important role for TLR3 in sensing viruses in the CNS. 
This is supported by 2 independent studies on TLR3 and West Nile 
virus infection (20, 21). While both reports identified key roles 
for TLR3 in innate recognition of West Nile virus infection, the 
2 studies differ with respect to whether TLR3 plays a beneficial or 
deleterious role for the host during the infection.
In vitro studies with astrocytes have previously shown that HSV-1 
and HSV-2 have the capacity to replicate in this cell type and that 
recombinant IFNs inhibit the viral propagation process (34, 35). 
One study has proposed a role for type III IFN in restricting HSV-1 
replication in vitro in astrocytes (35). However, in our model, IFN-λ 
receptor deficiency did not affect development of disease in the 
CNS after HSV-2 infection (3). Collectively, our present work pro-
vides in vivo evidence of physiological importance for the previ-
ously reported HSV replication in astrocyte cultures, which could 
be inhibited by type I IFN (34). In addition, our work demonstrates 
that the HSV-induced IFN response in astrocytes is mediated 
through a TLR3-dependent pathway.
Work by Bedoui and associates has recently shown that Tlr3–/– 
mice have impaired development of virus-specific CD8+ T cells in a 
model for cutaneous HSV-1 infection (28). In our model, we found 
similar levels of CD8+ T cells in the spleen of WT and Tlr3–/– mice 
at day 6 after vaginal HSV-2 infection. Moreover, we did not find 
recruitment of CD8+ T cells to the lumbar medulla spinalis (Sup-
plemental Figure 5, D–F). These data argue against a role for the 
adaptive immune system in control of HSV-2 in the CNS in this 
model. Presently, we do not know whether the findings obtained 
in the current study on HSV-2 will also apply in a model for HSV-1 
encephalitis after initial infection in the periphery (e.g., the ocular 
infection model) (36). It is of note, however, that the IFN response 
to HSV infection in astrocytes in vitro was dependent on TLR3 for 
both HSV-1 and HSV-2.
We did not find a global defect in activation of innate immune 
responses in Tlr3–/– mice, and we present data demonstrating that 
most PRRs reported to detect HSV are expressed in the CNS dur-
ing HSV infection. This suggests that other HSV-sensing PRRs are 
still operative in the CNS and responsible for the strong innate 
response observed p.i. in the Tlr3–/– mice. At this stage, we cannot 
explain why other HSV-sensing PRRs fail to compensate for the 
lack of TLR3. By contrast, Ifnar–/– mice fail to induce expression of 
most PRRs after HSV infection (Supplemental Figure 2B), which 
could contribute to more severe disease development in these 
mice. By using an intraperitoneal infection model for HSV-1, Kurt-
Jones et al. have previously reported that Tlr2–/– mice are strongly 
impaired in inducing an inflammatory response, which renders the 
mouse resistant to encephalitis in this model (10). In our model, 
Tlr2 and Tlr9 double-deficient mice were indistinguishable from 
WT mice with respect to expression of IFNs and inflammatory 
genes in the medulla spinalis. In an intranasal or corneal HSV-1 
infection model, Myd88–/– mice have previously been reported to 
develop lethal encephalitis, mainly due to uncontrolled infection. 
These data suggest a complex role for TLR2 and other TLRs in 
the immune response to HSV infections, by contributing to both 
antiviral defense and immunopathology (36, 37). We have recently 
reported the identification of IFI16 and its murine ortholog, 
Ifi204, as intracellular sensors of HSV-1 DNA (17). It will be inter-
esting to determine whether IFI16/Ifi204 or other intracellular 
PRRs play a role in immunological control of HSV in the CNS.
Defects in TLR3, TRAF3, and STAT1 function render humans 
highly susceptible to HSV-1 encephalitis (5, 23, 24), and a TLR3-
deficient patient with repeated HSV-2 Mollaret meningitis has 
been reported (26). In this work, we report that TLR3 deficiency 
in mice, like that in humans, leads to impaired restriction of HSV 
infection in the CNS. We propose that TLR3 acts in astrocytes to 
sense HSV-2 infection in the CNS, leading to local autocrine and 
paracrine IFN-β production, which restricts the virus in the local 
environment in the lumbar medulla spinalis immediately after 
entry into the CNS.
Methods
Mice. Female mice used in this study were age matched (minimum, 8 weeks old; 
maximum, 12 weeks old). Tlr3–/– and WT (B6;129S) mice were purchased from 
The Jackson Laboratory. C57BL/6J and Tlr2 and Tlr9 double-deficient mice 
were bred at Taconic M&B, and Ifnar–/– mice on C57BL/6J background were 
bred at University of Southern Denmark or at University of Copenhagen.
Viruses and reagents. MEM, DMEM, Iscove’s Modified Dulbecco’s Media 
(IMDM), and RPMI 1640 growth media were obtained from BioWhittaker 
and supplemented with 200 IU/ml penicillin, 200 μg/ml streptomycin, and 
LPS-free FCS (BioWhittaker). Depo-Provera (Pfizer), Heparin (Leo Phar-
ma), Brefeldin A (Sigma-Aldrich), IFN-β (PBL), isoflurane (Baxter), and 
ProLong Gold, DAPI, TRIzol, Poly I:C (all from Invitrogen) were used in the 
experiments described below. The viruses, HSV-2 (333 strain) and HSV-1 
(KOS strain), were amplified in Vero cells and used at 0.1 MOI for in vitro 
stimulation. Sendai virus (SeV, Cantell strain) was used at 0.001 MOI.
Murine intravaginal HSV-2 model. For vaginal HSV-2 infection, mice were 
pretreated by subcutaneous injection of 2 mg Depo-Provera. Five days 
later, mice were anesthetized with isoflurane and inoculated intravaginally 
with 20 μl HSV-2 (6.7 × 104 PFUs) in IMDM or with media alone. Subse-
quently, mice were placed on their backs and maintained under anesthetics 
for 10 minutes. Vaginal fluids were collected by washing twice with 250 μl 
IMDM. Genitally infected mice were examined daily and scored for vaginal 
inflammation, neurological illness, and death. The severity of disease was 
graded using the following scores: 0, healthy; 1, genital erythema; 2, moder-
ate genital inflammation; 3, purulent genital lesion and/or generally bad 
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condition; and 4, hind limb paralysis. Mice reaching score 4 were killed. 
Pathological examination was carried out for vagina, bladder, rectum, 
medulla spinalis, and cerebrum of mice at day 6 p.i.
Immunohistochemistry. Anesthetized mice were subjected to perfusion with 
10% formalin, and cerebrum and medulla spinalis tissue were subsequently 
excised. Tissues were cut into sections and left in 20%–30% sucrose solu-
tion for 4 days. Sections were embedded in OCT solution (Tissue-Tek) and 
frozen. For H&E and CD45+ staining, the tissues were postfixed in forma-
lin and embedded in paraffin. Four-μm-thick sections were mounted on 
glass slides and stained with H&E. Antibody retrieval was performed in the 
autostainer using standard CCI solution (pH 8; Ventana Medical Systems). 
IHC stainings with anti-CD45 (Dako) and anti–HSV-2 (Dako) antibodies, 
diluted 1:100 and 1:1,000, respectively, were performed on a BenchMark 
XT automated slide stainer (Ventana Medical Systems) according to the 
manufacturer’s instructions. HRP-labeled primary antibodies were visual-
ized using UltraView Universal DAB detection system (Ventana Medical 
Systems) and developed with chromagen diaminobenzidine (DAB). Finally, 
the slides were washed in rinse water, counterstained in Mayer’s hematoxy-
lin, dehydrated, and cover slipped.
Confocal microscopy of tissue sections. For astrocyte and neuronal staining, 
30-μm cryosections (HM 500 OM, Mikrom) were incubated in TEG buffer 
(10 mM Tris Base, 0.5 mM EGTA, pH 9) at 60°C overnight (O.N.) and sub-
sequently treated with methanolic H2O2 (3% H2O2 and 1% absolute metha-
nol) for 30 minutes. The sections were washed and incubated with primary 
antibodies at 4°C O.N., including rabbit polyclonal anti–HSV-2 (1:500; 
Dako), mouse anti–Neuronal Nuclei (NeuN) (1:300; Chemcon), mouse 
anti-GFAP (1:400; Sigma-Aldrich), and mouse anti-S100 (1:200; Abcam). 
The secondary antibodies, chicken anti-rabbit Alexa Fluor 488 and donkey 
anti-mouse Alexa Fluor 568 (Invitrogen), were used at 1:500 dilutions for 
1 hour at 20°C. Nuclei were stained with DAPI. The sections were washed 
5 times in 0.3% Triton-X in TBS and mounted in ProLong Gold. Stainings 
were imaged on a Zeiss LSM 710 laser scanning microscope, using a C-Apo 
40 × 1.2 water immersion lens. Zen 2010 acquisition software and ImageJ 
(http://rsbweb.nih.gov/ij/) were used for making collapsed z-stacks.
Confocal microscopy of primary astrocytes. Cells grown on glass cover slips 
were infected with HSV-2 (6 hours). Two μg/ml Brefeldin A was added 
to the culture 1 hour p.i. Cells were fixed in methanol and permeabilized 
in 0.5% Triton X-100. Cover slips were preincubated in 5% BSA/0.05% 
Tween20/PBS and costained at 4°C O.N. with primary antibodies directed 
against IFN-β (PBL; 1:100) and VP5 (Abcam; 1:200) and secondary Alexa 
Fluor 488– and Alexa Fluor 647–labeled antibodies (1:500) for 1 hour. 
Cover slips were mounted and imaged, as described above, using a plan-
apo 63 × 1.4 oil immersion lens (Zeiss).
Virus plaque assay. Organs were isolated, immediately put on dry ice, 
and stored at –80°C until use. Organs were thawed and homogenized in 
the appropriate solutions and pelleted by centrifugation at 1,600 g for 
30 minutes. Supernatants were used for plaque assay. In the case of vaginal 
washes and cell supernatants, samples were used directly for plaque titra-
tion after thawing. Vero cells were seeded in 5-cm-diameter plates in MEM 
with 5% FCS; the next day, cells were incubated with 100 μl serial dilution 
of the samples with 400 μl MEM. After 1 hour, 8 ml of MEM containing 2% 
human immunoglobulin (CSL Behring) were added, and the plates were 
further incubated for 2 days. Cells were subsequently stained with 0.03% 
methylene blue to allow quantification of plaques.
Quantitative RT-PCR. Total RNA was extracted with TRIzol according 
to manufacturer’s recommendations. Briefly, cells were lysed in TRIzol 
and chloroform was added, followed by phase separation by centrifuga-
tion. RNA was precipitated with isopropanol and pelleted by centrifuga-
tion. Pellets were washed with 80% ethanol and redissolved in RNase-free 
water. For cDNA generation, RNA was subjected to reverse transcription 
with oligo(dT) as primer and Expand reverse transcriptase (both from 
Roche). Before quantitative RT-PCR, RNA was treated with DNase I 
(Ambion) to remove any contaminating DNA, the absence of which was 
confirmed in control experiments in which the reverse transcriptase 
enzyme was omitted. The High Pure RNA Isolation Kit (Roche) was used 
for isolation of mRNA from primary cells. The mRNAs were quantified 
using SYBR Green (Stratagene) with the following primers: Ifna, 5′-CGGT-
GATGAGCTACTGGC-3′ and 5′-TTTGTACCAGGAGTGTCAAGG-3′; 
Gapdh, 5′-CAATGTGTCCGTCGTGGA-3′ and 5′-GATGCCTGCTTCAC-
CACC-3′; Tlr2, 5′-GGCTCTTCTGGATCTTGGTG-3′ and 5′-GAGTCCG-
GAGGGAATAGAGG-3′; Tlr3, 5′-CTCTTGAACAACGCCCAACT-3′ and 
5′-GTCCACTTCAGCCCAGAGAA-3′; Tlr9, 5′-CATGGACGGGAACTGC-
TACT-3′ and 5′-GGCACCTTTGTGAGGTTGTT-3′; RIG-I, 5′-ATGGCAGA-
CAAAGAGGAGGA-3′ and 5′-TCGTGGAAGAAGGCTTTGAG-3′; MDA5, 
5′-ACAGAGGCCTGGAACGTAGA-3′ and 5′-CTGCCCATGTTGCTGT-
TATG-3′; Dai, 5′-TTCTAGAGGACGCCACCATT-3′ and 5′-CTTCTTTCTTC-
GGCTCTTCA-3′; Tnfa, 5′-GTAGCCCACGTCGTAGCAAAC-3′ and 5′-ATC-
GGCTGGCACTAGTT-3′; Ifi204, 5′-TGGTCCCAAACAAGTGATGGTGC-3′ 
and 5′-TCAGTTTCAGTAGCCACGGTAGCA-3′; and Cxcl10, 5′CGATGAC-
GGGCCAGTGAGAATG-3′ and 5′-TCAACACGTGGGCAGGATAGGCT-
3′. The Ifn-β mRNA was quantified by real-time PCR using the TaqMan 
gene expression assay Mm00439546_s1 and TaqMan RNA-to-CT 1-Step 
Kit (Applied Biosystems).
ELISA measurements. 100 μl of the vaginal wash or cell culture supernatants 
were used to detect CXCL10, according to the instructions of the manufacturer 
of the Mouse CXCL10 DuoSet ELISA Development System (R&D systems).
Primary cell isolation and in vitro stimulation. For isolation of glial cells from 
mice, neonatal cerebra were harvested, trypsinized for 25 minutes, and fil-
tered through a 70-μm pore size filter. Cells of 3 cerebra were then seeded 
on 1 uncoated 75 cm2 culture flask and incubated with 40 ml DMEM 
containing 10% FCS. The medium was replenished on days 1 and 4 after 
plating. Henceforth, either microglia or astrocytes were isolated. Microglia 
were isolated using the following method: on days 12–14 of culturing, 
microglia were isolated by shaking the flask at 250 rpm for 48 hours; cells 
were then pooled, centrifuged, and seeded at appropriate densities on 
96-well plates O.N. for further stimulation. Astrocytes were isolated using 
the following method: glial cells were passaged 2–3 times and shaken at 250 
rpm for 48 hours, supernatant was eliminated, and the remaining adherent 
cells were predominantly astrocytes (>93%). The purity of the astrocytes 
was checked by flow cytometry using Alexa Fluor 488–labeled anti-GFAP 
antibody (Invitrogen) and confocal microscopy. Astrocytes were seeded in 
24-well plates (2.4 × 105 cells/ml) and stimulated as indicated. For virus 
replication assay in astrocytes, cells were incubated with HSV-2 at 0.1 MOI 
for 6 hours. Nonadherent virus was removed by washing with DMEM. The 
virus content in the last wash was under the detection level in virus plaque 
assays. Further analysis of virus content was performed using the plaque 
assay described above and supernatants harvested 24 hours p.i. In some 
experiments, cells were treated with 25 IU/ml IFN-β 24 hours p.i.
Peritoneal and spleen cells were harvested from age-matched 6- and 
12-week-old female mice. Peritoneal cells were obtained by injecting PBS 
containing 5% FCS and 20 IU/ml heparin into the peritoneal cavity and 
washed repeatedly. Cells were washed, pooled, counted, and resuspended 
in RPMI containing 5% FCS. Spleens were gently homogenized manually 
in a glass homogenizer in RPMI supplemented with 10% FCS. Erythrocytes 
were removed by hemolysis. The cells were passed through a 70-μm pore 
size filter, pooled, washed, counted, and seeded 24 hours prior to stimula-
tion as indicated above.
Flow cytometry. The spleens were isolated as described above but not 
pooled. Isolation of cells from medulla spinalis was performed as isolation 
of neonatal cerebrum. Cells were first blocked for 15 minutes with 10% nor-
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mal goat serum (Dako) or rat IgG (Jackson ImmunoResearch Inc.) to pre-
vent nonspecific binding. For quantifying primary astrocytes cell culture, 
the cells were trypsinized, fixed in methanol, permeabilized in 0.5% Triton 
X-100, and blocked with mouse IgG (Jackson ImmunoResearch Inc.). The 
antibodies, anti-CD3 FITC (clone 17A2, Pharmingen), anti-CD8 PE (clone 
53-6.7, eBioscience or BD Pharmingen), anti-NK1.1 APC (clone PK136, BD 
Pharmingen), or Alexa Fluor 488–labeled anti-GFAP antibody (Invitrogen), 
were added and incubated for 15 minutes at 20°C in the dark. After wash 
in PBS/BSA/Azide (PBS, pH 7.4, supplemented with 0.5% BSA and 0.05% 
sodium azide), 7-AAD Via-Probe (BD Biosciences) was used to identify 
dead cells. Subsequently, the cells were analyzed or sorted on a FC500 flow 
cytometer (Beckman Coulter) or a FACSAria III (BD Biosciences). FlowJo 
software version 8.8.3 (Tree Star Inc.) was used for data analysis.
Statistics. The data are shown as mean ± SEM. The statistical significance 
was determined by 2-tailed Student’s t test or Wilcoxon rank sum test. For 
binary data, the Fisher’s exact test was used. P values of less than 0.05 were 
considered to be statistically significant.
Study approval. All described animal experiments have been reviewed and 
approved by Danish government authorities and, hence, comply with Dan-
ish laws (The Animal Experiments Inspectorate, Slotsholmsgade 10, 1216 
København K, Denmark).
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